Pharmaceutical company Eli Lilly and Company (LLY) is generating significant investor attention. Eli Lilly has made a $409M investment in AI-centered drug discovery and is partnering with Genetic Leap to develop RNA-based drugs. Record-breaking sales from Zepbound and Mounjaro and other potential blockbuster drugs have caused Eli Lilly to revise upwards their revenue guidance by $3bn. They also have promising earnings beyond 2025-2030. Several hedge funds are bullish about Eli Lilly's ESG stock.
A bold move to slash the price of its new obesity weight-loss drug, Zepbound, has been reported to potentially solve the biggest problem in the weight-loss drug market. Other weight-loss industry competitors took a hit following this move. Eli Lilly's weekly insulin shot met late-stage study goals. They are also planning acquisition of Morphic for better treatment outcomes in inflammatory bowel disease. A unique collaboration with OpenAI aims to discover novel medicines to combat drug-resistant bacteria. Eli Lilly reported positive topline results from their phase 3 trials of QWINT-1 and QWINT-3. Lastly, Billionaire investor, Ray Dalio, endorses Eli Lilly as a good growth stock.
Eli Lilly LLY News Analytics from Tue, 19 Mar 2024 07:00:00 GMT to Sun, 08 Sep 2024 09:42:00 GMT - Rating 9 - Information 8 - Rumor 7
